Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma
Open Access
- 13 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 5 (1), 1-12
- https://doi.org/10.1038/s41392-020-0111-4
Abstract
MYH9 has dual functions in tumors. However, its role in inducing tumor stemness in hepatocellular carcinoma (HCC) is not yet determined. Here, we found that MYH9 is an effective promoter of tumor stemness that facilitates hepatocellular carcinoma pathogenesis. Importantly, targeting MYH9 remarkably improved the survival of hepatocellular carcinoma-bearing mice and promoted sorafenib sensitivity of hepatocellular carcinoma cells in vivo. Mechanistic analysis suggested that MYH9 interacted with GSK3 beta and reduced its protein expression by ubiquitin-mediated degradation, which therefore dysregulated the beta-catenin destruction complex and induced the downstream tumor stemness phenotype, epithelial-mesenchymal transition, and c-Jun signaling in HCC. C-Jun transcriptionally stimulated MYH9 expression and formed an MYH9/GSK3 beta/beta-catenin/c-Jun feedback loop. X protein is a hepatitis B virus (HBV)-encoded key oncogenic protein that promotes HCC pathogenesis. Interestingly, we observed that HBV X protein (HBX) interacted with MYH9 and induced its expression by modulating GSK3 beta/beta-catenin/c-Jun signaling. Targeting MYH9 blocked HBX-induced GSK3 beta ubiquitination to activate the beta-catenin destruction complex and suppressed cancer stemness and EMT. Based on TCGA database analysis, MYH9 was found to be elevated and conferred poor prognosis for hepatocellular carcinoma patients. In clinical samples, high MYH9 expression levels predicted poor prognosis of hepatocellular carcinoma patients. These findings identify the suppression of MYH9 as an alternative approach for the effective eradication of CSC properties to inhibit cancer migration, invasion, growth, and sorafenib resistance in HCC patients. Our study demonstrated that MYH9 is a crucial therapeutic target in HCC.This publication has 50 references indexed in Scilit:
- Hepatitis B virus-induced hepatocellular carcinomaCancer Letters, 2014
- Clinicopathological Significance of NMIIA Overexpression in Human Gastric CancerInternational Journal of Molecular Sciences, 2012
- Epidemiology of Viral Hepatitis and Hepatocellular CarcinomaGastroenterology, 2012
- Nonmuscle myosin IIA is associated with poor prognosis of esophageal squamous cancerDiseases of the Esophagus, 2011
- Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-catenin signalingCancer Letters, 2011
- The role of non-muscle myosin IIA in aggregation and invasion of human MCF-7 breast cancer cellsThe International Journal of Developmental Biology, 2011
- DOMINE: a comprehensive collection of known and predicted domain-domain interactionsNucleic Acids Research, 2010
- Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinomaMolecular Cancer, 2010
- Non-muscle myosin II takes centre stage in cell adhesion and migrationNature Reviews Molecular Cell Biology, 2009
- Hepatitis B virus X protein is essential for the activation of Wnt/?-catenin signaling in hepatoma cellsHepatology, 2004